
|Videos|February 23, 2018
Long-Term Follow-Up Results From the ZUMA-1 Trial in Non-Hodgkin Lymphoma
Author(s)Sattva S. Neelapu, MD
Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses long-term findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory aggressive non-Hodgkin lymphoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma
4
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
5




















